FDA Lifts Holds on 2 Nivolumab Myeloma Trials

December 6, 2017 – The FDA has lifted partial clinical holds placed on the phase I CheckMate-039 and phase II CA204142 trials exploring nivolumab-based regimens in patients with relapsed/refractory multiple myeloma. The agency placed the partial holds on the studies in October, along with a third study, the phase III CheckMate-602 trial, also examining a nivolumab combination in myeloma. The partial hold on the phase III study remains in place, according to … (leggi tutto)